Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Orion’s Stalevo® tablets.
These generic Carbidopa, Levodopa and Entacapone tablets contain Carbidopa, Levodopa and Entacapone 25/100/200 mg, and 37.5/150/200 mg.
Generic Carbidopa, Levodopa and Entacapone tablets are indicated in the treatment of Parkinson’s disease.
These strengths of Stalevo® have annual sales of approximately $ 95 million in the US.
®Manufactured by Orion Corporation.
Marketed by Novartis
